ReviewEuropean journal of pharmacology2002
The discovery and status of sibutramine as an anti-obesity drug.
Review in European journal of pharmacology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00941382 (Double-blind, Randomized Clinical Trial to Evaluate Effect of Combination Therapy of Metformin and Sibutramine Versus Metformin or Sibutramine Monotherapy Over Weight, Adiposity, Glucose Metabolism and Inflammatory State in Obese Patients), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Double-blind, Randomized Clinical Trial to Evaluate Effect of Combination Therapy of Metformin and Sibutramine Versus Metformin or Sibutramine Monotherapy Over Weight, Adiposity, Glucose Metabolism and Inflammatory State in Obese Patients
Who cites it
18 citing papers in PubMed, 125 citations in OpenAlex.
- Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2005Trial
- Anti-obesity medications impacting the eye: An emerging concern - a narrative review.World journal of methodology · 2026Review
- Colorimetric and Reverse Fluorescence Dual-Signal Readout Immunochromatographic Assay for the Sensitive Determination of Sibutramine.ACS omega · 2024Article
- Adulteration of Weight Loss Supplements by the Illegal Addition of Synthetic Pharmaceuticals.Molecules (Basel, Switzerland) · 2021Article
- Effects of Ethanol Extracts fromMarine drugs · 2021Article
- Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists.Drug safety · 2019Review
- Rapid Surface Enhanced Raman Scattering (SERS) Detection of Sibutramine Hydrochloride in Pharmaceutical Capsules with a β-Cyclodextrin- Ag/Polyvivnyl Alcohol Hydrogel Substrate.Sensors (Basel, Switzerland) · 2017Article
- The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity.Therapeutic advances in chronic disease · 2016Review
- Study on health hazards through medicines purchased on the Internet: a cross-sectional investigation of the quality of anti-obesity medicines containing crude drugs as active ingredients.BMC complementary and alternative medicine · 2015Article
- Pharmacotherapy for obesity.Journal of menopausal medicine · 2014Review
- Identification and determination of synthetic pharmaceuticals as adulterants in eight common herbal weight loss supplements.Iranian Red Crescent medical journal · 2014Article
- Anti-obesity drugs: past, present and future.Disease models & mechanisms · 2012Review
- NPY receptors as potential targets for anti-obesity drug development.British journal of pharmacology · 2011Article
- Effects of sibutramine and rimonabant in rats trained to discriminate between 22- and 2-h food deprivation.Psychopharmacology · 2009Article
- Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome.Core evidence · 2008Article
- Effects of the cannabinoid antagonist SR141716 (rimonabant) and d-amphetamine on palatable food and food pellet intake in non-human primates.Pharmacology, biochemistry, and behavior · 2007Article
- Central nervous system biogenic amine targets for control of appetite and energy expenditure.Endocrine · 2006Review
- A benefit-risk assessment of sibutramine in the management of obesity.Drug safety · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sibutramine is a serotonin-norepinephrine reuptake inhibitor indicated for the management of obesity in conjunction with a reduced calorie diet. Though sibutramine was originally evaluated for possible use as an antidepressant, its research development was eventually redirected to evaluate it as an anorexiant. The pharmacological mechanisms by which sibutramine exerts its weight loss effect are likely due to a combination of reduced appetite, feelings of satiety, and possibly the induction of thermogenesis. Its efficacy for inducing an initial weight-loss and the subsequent maintenance of the weight-loss is well proven in short- and long-term clinical trials of up to 2 years duration. In general, sibutramine has been well tolerated. Increases in blood pressure and heart rate are possible adverse effects that require regular monitoring. Sibutramine is one of the few established and well-proven agents for obesity available for use today and should be considered effective in the management of patients requiring pharmacotherapy as part of the multi-modal approach to weight-loss.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.